|Day's Range||34.27 - 34.47|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||24.48|
|Dividend & Yield||1.03 (3.00%)|
|1y Target Est||N/A|
Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).
Puma Biotechnology Inc (NASDAQ: PBYI ) popped 88 percent Monday on news that its neratinib candidate , an early-stage breast cancer treatment for human epidermal growth factor receptor-2 (HER2) positive ...
Incyte stock popped to a month-high Thursday after its immuno-oncology drug proved effective in matchups with Merck's Keytruda and Bristol's Opdivo.